AC Immune Stock

AC Immune Dividend 2024

AC Immune Dividend

0 CHF

AC Immune Dividend yield

Ticker

ACIU

ISIN

CH0329023102

WKN

A2AR5F

How much dividend does AC Immune 2024 pay?

According to the latest status from December 2024, AC Immune paid a total of 0 CHF per share in dividends within the last 12 months. With the current AC Immune price of 2.83 CHF, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical AC Immune Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the AC Immune Dividend Safe?

AC Immune has been increasing the dividend for 0 years.

Over the past 10 years, AC Immune has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding AC Immune's Dividend Distributions

AC Immune’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining AC Immune's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

AC Immune's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in AC Immune’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

AC Immune Aktienanalyse

What does AC Immune do?

AC Immune SA is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of neurodegenerative diseases as well as cancer. It was founded in 2003 by a group of leading researchers in the field of neurodegeneration and is based in Lausanne, Switzerland. The company has established itself as one of the leading companies in Alzheimer's research in recent years. AC Immune SA focuses on developing drugs targeting protein aggregation that occurs in Alzheimer's and other neurodegenerative diseases in the brain. It has developed an innovative platform technology that allows for the development of specific antibodies that selectively bind to certain toxic or disease-causing proteins. AC Immune has developed a variety of proprietary technologies and platforms that enable rapid and efficient identification, testing, and optimization of therapeutics. Its main products are antibodies that therapeutically target Alzheimer's, Parkinson's, TAU, and Alpha-Synuclein prions. These antibodies that target protein disease-related plaques help slow disease progression and alleviate symptoms. AC Immune has also developed and tested drugs for cancer treatment. The company operates in two main segments: research and development, as well as clinical studies. It has a strong pipeline of products in development that are in various stages of clinical trials. These products target various diseases including Alzheimer's, Parkinson's, advanced stage cancer, prion diseases, neurodegenerative sanatoria, and Down syndrome. AC Immune SA collaborates closely with various academic research institutions, biotechnology companies, pharmaceutical companies, and government agencies to bring innovative therapies to market. It has formed numerous partnerships and alliances with renowned partners in the pharmaceutical, biotech, and life science industries to accelerate the translation of promising therapeutic approaches into clinical applications. Recently, AC Immune SA announced a partnership with Genentech, a leading company in the development of biological therapies and diagnostic procedures. The two companies are working together to develop treatments for Alzheimer's and several other neurodegenerative diseases. Another example is the collaboration with Eli Lilly and Company for the use of ACI-3024 in the fight against tauopathies, including Alzheimer's disease and progressive supranuclear palsy. AC Immune SA has a strong foundation in scientific research and development, as well as in the commercialization of therapeutics. The company has a comprehensive product pipeline aimed at developing innovative therapy options for patients with neurodegenerative diseases and cancer. With its proprietary technology platform and partnerships with leading companies in the biotech and pharmaceutical industries, AC Immune SA has great potential to make significant advances in the development of therapies that improve patients' lives and enhance their quality of life. AC Immune is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about AC Immune stock

How much dividend does AC Immune pay?

Over the past 12 months, AC Immune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AC Immune is expected to pay a dividend of 0 CHF.

What is the dividend yield of AC Immune?

The current dividend yield of AC Immune is .

When does AC Immune pay dividends?

AC Immune pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AC Immune?

AC Immune paid dividends every year for the past 0 years.

What is the dividend of AC Immune?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is AC Immune located?

AC Immune is assigned to the 'Health' sector.

Wann musste ich die Aktien von AC Immune kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AC Immune from 12/5/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did AC Immune pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of AC Immune in the year 2023?

In the year 2023, AC Immune distributed 0 CHF as dividends.

In which currency does AC Immune pay out the dividend?

The dividends of AC Immune are distributed in CHF.

Andere Kennzahlen von AC Immune

Our stock analysis for AC Immune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AC Immune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.